Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Product sales	$ 4,157	$ 76
Product royalty revenues	1,406	3,407	$ 1,773
Research and development reimbursements	909	12,712	2,783
Contract revenue	41,759	22,749	6,800
Total revenues	48,231	38,944	11,356
Cost of sales	8,101	4,939	2,082
Expenses:
Research and development	20,624	34,285	53,327
Selling, general and administrative	54,685	38,460	12,349
Total expenses	75,309	72,745	65,676
Loss from operations	(35,179)	(38,740)	(56,402)
Interest expense, net	(2,518)	(2,016)	(903)
Derivative (loss) gain		(13,167)	121
Other income (expense), net	25	(295)	(210)
Net loss	$ (37,672)	$ (54,218)	$ (57,394)
Basic and diluted loss per share	$ (0.72)	$ (1.12)	$ (1.51)
Weighted average common stock shares outstanding, basic and diluted	52,384,876	48,355,200	37,941,044